A corporate account gives you access to licensed reports and subscriptions, the latest news, a personalized dashboard, and weekly emails with news and data.
Market Scope
Trusted Global Partner of Industry and Medical Professionals for Ophthalmic Market Research, Primary Research, Independent Perspective, & Objective Analysis
Choose Your Experience
Over 500 Clients, Large & Small from Around the World, Trust Market Scope Data & Analysis
Latest Market Reports
Market Scope's industry reports are meticulously prepared by a dedicated team of in-house consultants/analysts with over 100 years of collective experience.
- 269
Comprehensive Pages
- 8
Geographic and Economic Breakouts
- 5
Year Market Forecasts
- 52
Diseases Analyzed
2025 Cornea Products Market Report: Global Analysis for 2024 to 2030, December, 2025
The “2025 Cornea Products Market Report” delivers an in-depth analysis of the global cornea market, highlighting the latest advances in transplantation, crosslinking, and therapeutic devices aimed at restoring and preserving vision. The report estimates disease prevalence across six major corneal conditions and examines evolving treatment approaches, including cornea transplants, therapeutic lenses, phototherapeutic keratectomy (PTK), intrastromal ring segments, and corneal crosslinking.
It also explores the global ecosystem that supports cornea care—spanning organ donation systems, regulatory environments, and the pivotal roles of cornea specialists, eye banks, and nonprofit organizations.
This 2025 edition evaluates more than 70 products from over 50 companies, with forecasts for unit demand and revenue growth through 2030. It features analysis of emerging pipeline technologies yet to generate revenue and profiles 12 leading market participants shaping the future of cornea treatment.
Latest Industry News & Trends
10/21/2026
ESCRSIOLLaserMeetingNewsletterRefractiveSurgical
Lens-vs.-Laser Debate Heats Up at ESCRS Congress as New Refractive Technologies are Launched
The long-running debate between laser- and lens-based refractive surgery intensified at the 2026 ESCRS congress in London, where new product launches and packed scientific sessions underscored a ma...
10/21/2026
AIDealsDiagnosticESCRSMeetingNewsletter
Futures Forum Highlights Higher Investment Bar, Looks at AI Concerns
A common theme at the 2026 Ophthalmology Futures European Forum was that capital and innovation remain available, but the bar for both has risen. The forum was held Sept. 10 at Glaziers Hall on the...
10/21/2026
Dry EyeNewsletterPharmaRevenue
Miticides to Treat Dry Eye Climbing Toward $1 Billion in Annual Sales
Tarsus Pharmaceuticals is behind the rapid growth of the miticide category of dry-eye related pharmaceuticals in the US. Market Scope expects US sales in the miticide category to soon exceed $1 bil...
10/21/2026
DealsGene TherapyNewsletterRetina
Gene Therapy Reclaims Top Spot in Ophthalmic Fundraising
Ophthalmic gene therapy fundraising has reached nearly $1.3 billion in 2026, propelled by major investments in Beacon Therapeutics, Regenxbio, and MeiraGTx. Beacon closed a Series C round in Januar...
10/21/2026
DealsIOLNewsletterRetina
Saunders Departs Bausch + Lomb, as Chairman Appio Takes Over
Bausch + Lomb announced Oct. 12 that CEO Brent Saunders would leave the company immediately, with chairman Thomas Appio taking over as interim CEO. Appio also is CEO of Bausch Health. Saunders had ...
10/21/2026
IOLNewsletterRegulation
Rayner Launches RayOne Galaxy IOL in US after Receiving FDA Approval
UK-based Rayner announced Sept. 24 that its RayOne Galaxy and RayOne Galaxy Toric IOLs were commercially available in the US after the lenses gained FDA approval. The Galaxy is the first-ever spira...
10/21/2026
AcquisitionsDealsNewsletterRetina
Alcon Acquires Neurotech and its MacTel Treatment Encelto for $550 Million
Alcon announced Oct. 20 that it had acquired Neurotech Pharmaceuticals, maker of Encelto for macular telangiectasia Type 2 (MacTel), for $550 million. Alcon said that it might be required to make a...
10/21/2026
MyopiaNewsletterRegulation
FDA Panel Meeting for Sydnexis’ Rejected Myopia Drop Set for Oct. 30
Sydnexis reported Sept. 24 that the US FDA had set Oct. 30 as the date for an advisory committee and open public hearing to review the new drug application (NDA) for SYD-101, an atropine eye drop c...
Provider Surveys & Interviews
Grab a seat at the table and join the thousands of ophthalmologists and optometrists from over 60 countries who are helping shape the next generation of diagnostics, pharmaceuticals, devices, and equipment by sharing your opinion and experience. Make your voice heard!
Choose Your Own Adventure
Participation options include weekly polls, special sponsored surveys, syndicated quarterly surveys, focus groups, and interviews, each with varying levels of honoraria.
Safe, Secure & On Any Device
We follow all industry standards to ensure confidentiality between participants and clients. Start and stop surveys anytime on our free Market Scope+ App or on desktop, each with a personalized dashboard just for you.
Pre-Qualified Invitations
We individually verify all potential participants before each survey or interview, ensuring that only licensed eye care professionals are invited and they are never kicked out or disqualified.
Better Data = Better Decisions
A team of industry experts and analysts review each data point, so you can be confident in the results and trends provided in our reports.
Download the Market Scope+ app to get started!
Market Scope Methodology
A Multi-Step Approach for Accurate & Timely Data
Proprietary data
- 20+ years of physician survey data
- Disease models
- Cultivated database of physicians, ASCs, and hospitals
- Insight from our team of in-house industry experts
Public data
- Attendance and participation at major, worldwide meetings
- Public health systems and registries
- Clinical study data
- Analysis of company-published financial reports
Join Market Scope Today
Register A Corporate Account
Register A Clinical Account
A clinical account gives you access to survey participation and results, weekly polls, benchmark reports, a searchable news archive, and more on a personalized dashboard.